Voyager Therapeutics (VYGR) Accounts Payables (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Accounts Payables data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 3.38% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 3.38% YoY), and the FY2025 full-year result was $5.0 million, up 25.45% from the prior year.
• Accounts Payables retreated to $2.7 million in Q1 2026, from $5.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.6 million in Q1 2024 to a low of $1.2 million in Q1 2022.
• A 5-year average of $2.8 million and a median of $2.6 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 347.04% in 2022 and plunged 65.25% in 2025, its largest moves.
• Tracing VYGR's Accounts Payables over 5 years: stood at $2.6 million in 2022, then slumped by 37.49% to $1.6 million in 2023, then soared by 149.13% to $4.0 million in 2024, then grew by 25.45% to $5.0 million in 2025, then slumped by 45.68% to $2.7 million in 2026.
• Business Quant data shows VYGR's Accounts Payables at $2.7 million in Q1 2026, $5.0 million in Q4 2025, and $2.1 million in Q3 2025.